Literature DB >> 10981078

The renin-angiotensin system antagonism in the treatment of hypertension.

J D Bisognano1, R J Cody.   

Abstract

The effective treatment of hypertension is associated with improved mortality and morbidity from diseases such as stroke, congestive heart failure, and renal failure. Use of medications that target the renin-angiotensin system for the treatment of hypertension can often achieve the desired decrease in blood pressure while causing a minimum of unwanted side effects. In this paper, the principles of the renin-angiotensin system antagonism are described. The approach to using these medications is discussed with special attention to specific indications as well as common side effects.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10981078     DOI： 10.1007/s11906-999-0033-6

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  12 in total

Review 1.  Angiotensin converting enzyme inhibition and its impact on cardiovascular disease.

Authors:  H Gavras
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

Review 2.  Angiotensin receptors and their antagonists.

Authors:  T L Goodfriend; M E Elliott; K J Catt
Journal:  N Engl J Med       Date:  1996-06-20       Impact factor: 91.245

3.  Combination therapy with an angiotensin converting enzyme inhibitor and an angiotensin-II receptor antagonist for refractory essential hypertension.

Authors:  J D Bisognano; L D Horwitz
Journal:  West J Med       Date:  1998-04

4.  Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey.

Authors:  J Goldberg; G Flowerdew; E Smith; J A Brody; M O Tso
Journal:  Am J Epidemiol       Date:  1988-10       Impact factor: 4.897

5.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

Review 6.  Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy.

Authors:  M Hanssens; M J Keirse; F Vankelecom; F A Van Assche
Journal:  Obstet Gynecol       Date:  1991-07       Impact factor: 7.661

Review 7.  Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.

Authors:  A J Wagstaff; R Davis; D McTavish
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

8.  Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog.

Authors:  B G Zimmerman; P C Raich; R J Vavrek; J M Stewart
Journal:  Circ Res       Date:  1990-01       Impact factor: 17.367

9.  Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension.

Authors:  O Bertel; F R Bühler; W Kiowski; B E Lütold
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

10.  Pulmonary function and airway responsiveness during long-term therapy with captopril.

Authors:  L P Boulet; J Milot; N Lampron; Y Lacourcière
Journal:  JAMA       Date:  1989-01-20       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.